Dr. Suzanne Merrill

And unfortunately, the TRBT is so critically important for these patients as, again, it is one of their mainstays of treatment to get that cancer out fully, accurately stage and grade the patient, get them on that right journey. And there is a lot of data out there and we all know it that we do leave tumor behind.

And unfortunately, the TRBT is so critically important for these patients as, again, it is one of their mainstays of treatment to get that cancer out fully, accurately stage and grade the patient, get them on that right journey. And there is a lot of data out there and we all know it that we do leave tumor behind.

And unfortunately, the TRBT is so critically important for these patients as, again, it is one of their mainstays of treatment to get that cancer out fully, accurately stage and grade the patient, get them on that right journey. And there is a lot of data out there and we all know it that we do leave tumor behind.

There's reports up to, you know, 76% that residual tumor is left behind after the first TRBT. And that's a high number. And so again, this technology can really help to make sure that we do the best job we can for our patients, you know, at those TRBT settings, initial TRBT, repeat TRBTs, and getting all that cancer out that we can.

There's reports up to, you know, 76% that residual tumor is left behind after the first TRBT. And that's a high number. And so again, this technology can really help to make sure that we do the best job we can for our patients, you know, at those TRBT settings, initial TRBT, repeat TRBTs, and getting all that cancer out that we can.

There's reports up to, you know, 76% that residual tumor is left behind after the first TRBT. And that's a high number. And so again, this technology can really help to make sure that we do the best job we can for our patients, you know, at those TRBT settings, initial TRBT, repeat TRBTs, and getting all that cancer out that we can.

Yeah, that's very true. I think the data really over time has... shown us that blue light is a technology that should be offered to our patients, that it has good enough evidence behind it, that it can impact our patient's course of disease and outcome.

Yeah, that's very true. I think the data really over time has... shown us that blue light is a technology that should be offered to our patients, that it has good enough evidence behind it, that it can impact our patient's course of disease and outcome.

Yeah, that's very true. I think the data really over time has... shown us that blue light is a technology that should be offered to our patients, that it has good enough evidence behind it, that it can impact our patient's course of disease and outcome.

Even back in 2013, there was a meta-analysis of nine studies, which ultimately showed that detection of TA and T1 lesions may be up to 25% greater with blue light cystoscopy and use of cis-fueled than compared to white light.

Even back in 2013, there was a meta-analysis of nine studies, which ultimately showed that detection of TA and T1 lesions may be up to 25% greater with blue light cystoscopy and use of cis-fueled than compared to white light.

Even back in 2013, there was a meta-analysis of nine studies, which ultimately showed that detection of TA and T1 lesions may be up to 25% greater with blue light cystoscopy and use of cis-fueled than compared to white light.

And overall, this translated looking at really the raw data from this meta-analysis that the rate of recurrence with use of blue light can be reduced by about 11%, and it can certainly prolong the time to recurrence by about seven-ish months. So some pretty impactful evidence behind this technology.

And overall, this translated looking at really the raw data from this meta-analysis that the rate of recurrence with use of blue light can be reduced by about 11%, and it can certainly prolong the time to recurrence by about seven-ish months. So some pretty impactful evidence behind this technology.

And overall, this translated looking at really the raw data from this meta-analysis that the rate of recurrence with use of blue light can be reduced by about 11%, and it can certainly prolong the time to recurrence by about seven-ish months. So some pretty impactful evidence behind this technology.

Yeah, no, that's a really good point to bring up. You know, I think at least right now, evidence hasn't really kind of panned out, you know, in regards to it. Does it get picked up by more variant histologies such as small cells, such as micropapillary cells? sarcomatoid, which we all know can be seen. It's more rare, but can be seen certainly in the superficial setting.

Yeah, no, that's a really good point to bring up. You know, I think at least right now, evidence hasn't really kind of panned out, you know, in regards to it. Does it get picked up by more variant histologies such as small cells, such as micropapillary cells? sarcomatoid, which we all know can be seen. It's more rare, but can be seen certainly in the superficial setting.

Yeah, no, that's a really good point to bring up. You know, I think at least right now, evidence hasn't really kind of panned out, you know, in regards to it. Does it get picked up by more variant histologies such as small cells, such as micropapillary cells? sarcomatoid, which we all know can be seen. It's more rare, but can be seen certainly in the superficial setting.

These studies, these randomized studies, multi-center perspective in nature that really set this optical imaging agent up for FDA approval and use today didn't really sort out the variant histology, if you will. What we know is that certainly it does get picked up more by more aggressive type lesions like CIS, but can certainly still be used in the low-grade setting.

These studies, these randomized studies, multi-center perspective in nature that really set this optical imaging agent up for FDA approval and use today didn't really sort out the variant histology, if you will. What we know is that certainly it does get picked up more by more aggressive type lesions like CIS, but can certainly still be used in the low-grade setting.